MeDucation· @MeDucationai · X·· 2 天前评分70
正文 · 机器翻译
来自 @stolaney1 的清晰、简明的 NATALEE OS 总结。大家容易混淆的细节是：NATALEE 使用 ribociclib 400 mg 持续 3 年，并纳入了高危、淋巴结阴性的 II 期疾病患者；而 monarchE 则对淋巴结阳性患者使用 abemaciclib 2 年。#ESMO26 #bcsm
68 浏览 · 1 赞 · 0 转发 · 1 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.orgNATALEE: OS data Adjuvant ribociclib in ER+ breast cancer 6 yr OS HR 0.809 (delta 2.1%) BCSS: 0.706 (delta 2.6%) 6 yr iDFS HR 0.741 (delta ~5%) DDFS: HR 0.744 @OncoAlert #ESMO26在 X 查看被引用的帖子
帖内回复
- Cohen carine@carinecccc
@MeDucationai @stolaney1 https://www.dropbox.com/scl/fi/m1mdzm1j4bizrytehetq1/The-unofficial-secret-stories-of-ESMO-2026.pdf?rlkey=j7tthl4e3q0bneoc23l5lskhc&st=113rm0kw&dl=0
来源：MeDucation · x.com